Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Department of Neurology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Curr Neuropharmacol. 2024;22(14):2272-2283. doi: 10.2174/1570159X22666240509092903.
The human central nervous system (CNS) has a limited capacity for regeneration and repair, as many other organs do. Partly as a result, neurological diseases are the leading cause of medical burden globally. Most neurological disorders cannot be cured, and primary treatments focus on managing their symptoms and slowing down their progression. Cell therapy for neurological disorders offers several therapeutic potentials and provides hope for many patients. Here we provide a general overview of cell therapy in neurological disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Wilson's disease (WD), stroke and traumatic brain injury (TBI), involving many forms of stem cells, including embryonic stem cells and induced pluripotent stem cells. We also address the current concerns and perspectives for the future. Most studies for cell therapy in neurological diseases are in the pre-clinical stage, and there is still a great need for further research to translate neural replacement and regenerative therapies into clinical settings.
人类中枢神经系统(CNS)与许多其他器官一样,其再生和修复能力有限。部分由于这个原因,神经疾病是全球医疗负担的主要原因。大多数神经疾病无法治愈,主要治疗方法侧重于控制其症状并减缓其进展。神经疾病的细胞疗法具有多种治疗潜力,为许多患者带来了希望。在这里,我们提供了神经疾病(如帕金森病(PD)、阿尔茨海默病(AD)、肌萎缩侧索硬化症(ALS)、威尔逊病(WD)、中风和创伤性脑损伤(TBI))中细胞疗法的概述,包括多种形式的干细胞,包括胚胎干细胞和诱导多能干细胞。我们还讨论了目前的关注问题和未来的展望。神经疾病细胞疗法的大多数研究处于临床前阶段,仍然需要进一步的研究,将神经替代和再生疗法转化为临床环境。